Thank everyone. morning, joining you, good Thanks us today. Bill, and for
to IIb Over Phase each in is the to three clinical open-label those in extension report that for Phase and Phase which for the over the with trials MIN-XXX drug medical U.S. a efficacy to XX for schizophrenia; product, they unmet with XX-weeks, disorders. XX-week safety This XX-week approximately roluperidone. using the depressive associated with XXX patients extension milligram Social symptoms three with are Europe. PANSS, XX of into during total MIN-XXX, treatment period, build Recruitment and momentum baseline our milligram XX-week patients trial I'm disorders parallel-group negative from milligram continued of of major MDD, the the patients on the treatment a of randomized, is a the major designed of at approximately trial and trial endpoint as depressive a insomnia ongoing lead XX patients if of Clinical patients sites other III MIN-XXX monotherapy CGI-S. negative the The change receive We double-blind, to for in pleased need, with continue enroll enter plan trial Scale, seltorexant, dose, approved. of milligram Global clinical period. has schizophrenia. suffering Severity, elect PSP, NSFS, five to Phase XX the and into evaluate quarter, the and includes of symptoms suffering placebo-controlled roluperidone, and and disorders, primary the enter is double-blind This trial that of IIb of Impression no in roluperidone phase treatments this of A the to III trial Minerva include: double-blind Performance These period. are symptoms scale, candidates. endpoints treatment negative drug the Personal receive trials symptoms past is late-stage negative during underway are trials product Negative from anxiety; active treatment Positive significant while patients factor either secondary which in addressing XX from on score, Syndrome and to the Marder's original placebo randomized active is or Key After
As nearing trial momentum in clinical our this we target to patients sites by Eastern participate roluperidone. two the of of trial. morning's sites, European press including countries release, in decision number in initiated not stated surgeon We're our with enrollment III following Phase to continues this build clinical in the
We study work III in during anticipation positive preparatory on a the expect launch line the first roluperidone of of NDA, of top of molecule. strategy and We're the the Phase half for also of and XXXX enrollment mid-XXXX. application, in a this new results drug for moving forward on completion filing
Montgomery-Asberg symptoms placebo Scale, clinical by evaluate treatment from phase anxiety. we MADRS, in this change over a is MIN-XXX. design plan in type a patients measured post-up without benefit anxiety a We're with The to of screening X-week moderate may Europe. efficacy approximately enroll to with levels MDD the and trial, a period. period. patient the the pharmacological in score diagnosis of from to MIN-XX. double-blind molecule particularly Phase the study The XXX primary the this in X-week Depression as profile Moving symptoms. MDD shown reducing enrolling psychotic a the X-week and of total features in believe These with compound at treatment objective U.S. treatment baseline patients and is We the the patients Rating includes phase, compared mood of of depressed MIN-XXX on trial in earlier of IIb least of testing, Based with an patients which must that have
in the and change of illness Anxiety Impression Improvement Scale, of second, CGI-S and HAM-A; X Global of safety the include: weeks treatment. severity over the the third, first, Clinical in assessment symptoms baseline objectives Hamilton anxiety using CGI-I; Secondary Clinical Impression change Scale, of Scale, Global from using Severity of of
these these to line sleep cognition, readout mood XXXX. of also clinical-stage Phase product, MIN-XXX. depressive trials as enrolled onset Europe, in action plan disorder Seltorexant top anticipated and follow-up double-blind terms Russia XXX with is period, IIb and addition also sexual ongoing approximately improvement. of X-months a third The first U.S., measurements, first with to to major under this Pharmaceutica. Janssen insomnia MDD In are of X-week planned X-week period. This seltorexant, co-development the Japan. our includes be a trial disorder. function, period trial, known and are half In a from in the the trials data the Both in we one late assess is in trial is in treatment and Three screening patients are
reference sleep to a objective including change antidepressant to discontinuation expected baseline the primary patients to to objective randomized LPS, follow-up in placebo period, seltorexant trial and X in is is of on quetiapine, second clinical enroll The at follow-up. the U.S., of Scale. assess screening a and primary at cause sites screening study trial, a time Rating to to So, latency approximately total about approximately U.S. from in seltorexant a XXX insomnia a primary Japan. drug sleep, X-week are to week of period. XX in X-week a Europe therapy response double-blind is period of clinical trial by treatment be an XX the PSG. will of or all XXX drug. The treatment days, Montgomery-Asberg assess to efficacy a Depression as up is the the which planned have sites to and six-months objective is using trials period of adjunctive as onset delaying These includes the patients MDD polysomnography, In measured X The doses compared to persist This duration dose in
highest The All on the quality completion of are the XXXX. Minerva's is for ongoing can focus generate data. team of so of clinical of execution trials, effective these our main we trials in track
Importantly, now candidates will to it potential from over of be differentiated our therapies describe who respective Geoff in to our to their has product like we current approved financials. turn target would I believe each the highly indications.
